Mederi Therapeutics Inc. has announced it has secured $18.5 million in funding comprised of Series B preferred stock and venture debt.

Mederi Therapeutics, based in Greenwich, Conn., manufactures and markets medical devices that deliver radiofrequency energy to treat disease.

Participants in the funding round included venture capital firm Acadia Woods Partners, LLC, and Respiratory Diagnostics Inc. (a subsidiary of Bio-Rad Laboratories, Inc.).

Mederi indicated that the funds will be used to support and expand on the use of Mederi’s Stretta therapy for GERD and Secca therapy for bowel incontinence.